Press Releases

 
Press Releases
  Date Title and Summary View
May 2, 2017
First quarter revenue of $21.5 million, an increase of 26% compared to prior year periodFirst quarter Tuberculosis revenue of $18.5 million, an increase of 8% compared to prior year periodFirst quarter Tick-borne disease and other revenue of $3.0 million OXFORD, United Kingd...
Apr 19, 2017
OXFORD, United Kingdom and MARLBOROUGH, Mass., April 19, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced that it plans to relea...
Mar 23, 2017
OXFORD, United Kingdom and MARLBOROUGH, Mass., March 23, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced the release of national ...
Feb 28, 2017
Fourth quarter revenue of $23.7 million, an increase of 41% compared to prior year periodFourth quarter Tuberculosis revenue of $20.4 million, an increase of 22% compared to prior year periodFourth quarter Tick-borne disease and other revenue of $3.3 millionFull year 20...
Feb 22, 2017
OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced Dr. Peter Wrighton-Smit...
Feb 14, 2017
OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 14, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced that it plans to relea...
Feb 1, 2017
OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 01, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced Richard Altieri, Chief ...
Dec 21, 2016
OXFORD, United Kingdom and MARLBOROUGH, Mass., Dec. 21, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced that Dr....
Dec 8, 2016
OXFORD, United Kingdom and MARLBOROUGH, Mass., Dec. 08, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced that the New England Journal of Me...
Nov 17, 2016
OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 17, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced that Peter Wrighton-Sm...
Page:
1
... NextLast
= add release to Briefcase